% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nawroth:825201,
      author       = {Nawroth, T. and Johnson, R. and Krebs, L. and Khoshakhlagh,
                      P. and Langguth, P. and Hellmann, N. and Goerigk, G. and
                      Boesecke, P. and Bravin, A. and Duc, G Le and Szekely, N.
                      and Schweins, R.},
      title        = {{T}arget {N}anoparticles for {T}herapy - {SANS} and {DLS}
                      of {D}rug {C}arrier {L}iposomes and {P}olymer
                      {N}anoparticles},
      journal      = {Journal of physics / Conference Series},
      volume       = {746},
      number       = {1},
      issn         = {1742-6596},
      address      = {Bristol},
      publisher    = {IOP Publ.},
      reportid     = {FZJ-2016-07672},
      pages        = {012069 -},
      year         = {2016},
      abstract     = {T arget Nano-Pharmaceutics shall improve therapy and
                      diagnosis of severe diseases, e.g. cancer, by individual
                      targeting of drug-loaded nano-pharmaceuticals towards cancer
                      cells, and drug uptake receptors in other diseases. Specific
                      ligands, proteins or cofactors, which are recognized by the
                      diseased cells or cells of food and drug uptake, are bound
                      to the nanoparticle surface, and thus capable of directing
                      the drug carriers. The strategy has two branches: a) for
                      parenteral cancer medicine a ligand set (2-5 different,
                      surface-linked) are selected according to the biopsy
                      analysis of the patient tissue e.g. from tumor.; b) in the
                      oral drug delivery part the drug transport is enforced by
                      excipients/ detergents in combination with targeting
                      materials for cellular receptors resulting in an induced
                      drug uptake. Both targeting nanomaterials are characterized
                      by a combination of SANS + DLS and SAXS or ASAXS in a
                      feedback process during development by synthesis,
                      nanoparticle assembly and formulation.},
      cin          = {JCNS (München) ; Jülich Centre for Neutron Science JCNS
                      (München) ; JCNS-FRM-II},
      ddc          = {530},
      cid          = {I:(DE-Juel1)JCNS-FRM-II-20110218},
      pnm          = {6G15 - FRM II / MLZ (POF3-6G15) / 6G4 - Jülich Centre for
                      Neutron Research (JCNS) (POF3-623)},
      pid          = {G:(DE-HGF)POF3-6G15 / G:(DE-HGF)POF3-6G4},
      experiment   = {EXP:(DE-MLZ)KWS2-20140101},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000409470900069},
      doi          = {10.1088/1742-6596/746/1/012069},
      url          = {https://juser.fz-juelich.de/record/825201},
}